Person: KIRPINAR, İSMET
Now showing 1 - 10 of 12
- PublicationOpen AccessCOVID-19 Pandemic: Stress and Psychiatric Disorders(2021-02-01T00:00:00Z) KIRPINAR, İSMET; KIRPINAR, İSMETThe epidemic, which first started as viral pneumonia in Wuhan, China at the end of 2019 and is now known as Coronavirus disease-19 (COVID-19). rapidly spread to almost every part of the world and named a pandemic in March 2020. It is well known that psychiatric symptoms and syndromes, especially posttraumatic stress disorder, major depression, anxiety, and sleep disorders reach high prevalence values in natural or man-made disasters, Especially in infectious disease epidemics where mortality rates are high, patients, those who arc quarantined, and the whole society experience very intense mental stress and trauma. It is not easy to avoid psychological distress after facing highly fatal illnesses such as Ebola, severe acute respiratory syndrome (SARS), or COVID-19. When pandemics turn into a rapid and global disaster, the prevalence values of mental problems reach even higher levels. Combating mental disorders not only provides psychological well-being but also affects the course of the epidemic, as these disorders can delay efforts to fight epidemics.
- PublicationOpen AccessAssessing and Managing Delirium in Surgical and Internal Medicine: an Overview(2016-12-01) Kirpinar, Ismet; KIRPINAR, İSMETDelirium is most common neuropsychiatric disorder that affects patients in surgical and internal medicine clinics. It is defined as a transient, usually reversible organic mental disorder that has a rapid onset and fluctuating course. Clinically, delirium is an acute or subacute organic mental syndrome that is characterized by a disturbance in attention (reduced ability to direct, focus, sustain, and shift attention), awareness (reduced orientation to the environment), and other cognitive abilities (e.g., memory deficit and disorientation) and is not better explained by preexisting, established, or other evolving neurocognitive disorders. Studies have found that between 10% and 20% of all adult inpatients are diagnosed with delirium and that it occurs in up to 50% of elderly inpatients. Delirium itself is not a disease but rather a clinical syndrome, which results from an underlying disease. There is evidence from the history, physical examination, or laboratory findings that the disturbance is a physiological consequence of an underlying medical condition, substance intoxication or withdrawal, use of a medication, or a toxin exposure, or it is a combination of these factors. Accurate identification of underlying causes and risk factors is essential in early stage diagnosis and treatment. Treatment of delirium requires the treatment of the underlying causes. Psychotropic medications are used to comfort patients or enable better patient management. This study aims to review the clinical characteristics, etiological and risk factors, and different methods to obtain an accurate diagnosis and treatment of delirium.
- PublicationOpen AccessThe first male case with fluoxetine induced hair loss and review of the literature(2021-01-01T00:00:00Z) Karacan, FATMA; Tangilntiz, A.; KIRPINAR, İSMET; AKYÜZ KARACAN, FATMA; TANGİLNTİZ, AİSE; KIRPINAR, İSMETObjective: Fluoxetine is the drug of choice in the treatment of depression. It is widely preferred due to fewer side effects and greater tolerability. Hair loss is a frequent adverse effect that may occur by psychotropic drug use and that can remit by its cessation. Patients and methods: We present the diagnosis and treatment of a 26-year-old male patient. He was diagnosed with depression without psychotic features according to the DSM-V criteria and was administered fluoxetine in a dose of 20 mg/day. Results: Six weeks after the initiation of the fluoxetine treatment, the patient reported hair loss in the frontal area of the skull. These complaints regressed after cessation of drug. Conclusions: Hair loss appears to be a rare side effect of fluoxetine-based treatment. Dermatologists and psychiatrists must be informed about this adverse side effect. There might be differences in the risk of hair loss between the various SSRIs and the risk might be higher in female than in male. This male patient was the first case as far as we know in the literature. It should be kept in mind that hair loss may be observed in patients treated with fluoxetine and should be questioned in both male and female.
- PublicationOpen AccessCan we predict who will be more anxious and depressed in the COVID-19 ward?(2021-01-01T00:00:00Z) Sahan, Ebru; Unal, Shafiga Mursalova; KIRPINAR, İSMET; ŞAHAN, EBRU; KIRPINAR, İSMETObjective: Hospitalized patients with COVID-19 are at high risk for anxiety and depression, but most studies about mental health during the pandemic included the general public, healthcare workers, and students. We aimed to explore the anxiety and depression levels, prevalence and predictors in patients hospitalized with COVID-19. Methods: In this cross-sectional, exploratory study, sociodemographic and clinical features of 281 patients with confirmed COVID-19 were explored. Patients underwent a comprehensive psychiatric assessment and the Hospital Anxiety and Depression Scale (HADS) was administered through a telephonic interview. Results: The mean age of the participants was 55.0 ± 14.9 years. One hundred forty-three (50.9%) patients were male, and 138 (49.1%) were female. Ninety-eight (34.9%) patients had significant levels of anxiety and 118 (42.0%) had significant levels of depression. Female gender, staying alone in a hospital room, early days of hospital stay, and any lifetime psychiatric disorder was associated with symptoms of anxiety. Being over 50 years of age, staying alone in a hospital room, and NSAID use before the week of hospital admission were associated with symptoms of depression. Anxiety and depression levels were lower when family members who tested positive for COVID-19 stayed in the same hospital room during treatment. Conclusion: Women, patients >50 years, patients who used NSAIDs before hospital admission, and those with lifetime psychiatric disorders may be at risk for anxiety and depressive symptoms in the COVID-19 ward. Allowing family members with COVID-19 to stay in the same hospital room may be associated with lower anxiety and depression levels.
- PublicationOpen AccessRelationship of Asymmetrical Dimethylarginine, Nitric Oxide, and Sustained Attention during Attack in Patients with Major Depressive Disorder(2014-01-01) CANPOLAT, Serpil; Kirpinar, Ismet; Deveci, ERDEM; Aksoy, Hulya; BAYRAKTUTAN, Zafer; EREN, Ibrahim; Demir, Recep; Selek, Salih; Aydin, Nazan; KIRPINAR, İSMET; DEVECİ, ERDEMAbstract We investigated the relationship of serum nitric oxide (NO) and asymmetrical dimethylarginine (ADMA) levels with cognitive functioning in patients with major depressive disorder (MDD). 41 MDD patients (Beck depression scale scores>16) and 44 controls were included in the study. Rey verbal learning and memory test, auditory consonant trigram test, digit span test, Wisconsin card sorting test, continuous performance task (TOVA), and Stroop test scores were found to be impaired in patients with major depressive disorder when compared to healthy controls. There was no significant difference between patient and control groups in terms of serum NO and ADMA. Serum NO levels were correlated with TOVA test error scores and Stroop test time scores, whereas serum ADMA levels were negatively correlated with TOVA test error scores. Metabolic detriments especially in relation to NO metabolism in frontal cortex and hypothalamus, psychomotor retardation, or loss of motivation may explain these deficits.
- PublicationOpen AccessEffects of Cognitive Behavioral Therapy, Existential Psychotherapy and Supportive Counselling on Facial Emotion Recognition Among Patients with Mild or Moderate Depression(2019-07-01) YILMAZ, ONUR; Kunduz, Merve; ÇOMBAŞ, MÜGE; ÖZTÜRK, AHMET; DEVECİ, ERDEM; KIRPINAR, İSMET; YILMAZ, ONUR; MIRÇIK, ALİ BARLAS; ÖZTÜRK, AHMET; DEVECİ, ERDEM; KIRPINAR, İSMETObjective: This study compared the effects of cognitive behavioral therapy (CBT), existential psychotherapy (ExP) and supportive counseling (SUP) on facial emotion recognition among mildly and moderately depressed patients. Methods: 21 patients for CBT, and 20 each for ExP and SUP groups with 60 healthy controls were investigated. Eight consecutive weekly sessions and following two monthly boosters were performed. Prior to the sessions, all subjects received Sociodemographic Data Form, the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-1), and Facial Emotion Recognition Test (FERT). Patients received Hamilton Depression Rating Scale (HDRS) and FERT at the onset and after weekly and booster sessions. Results: Patients' ability to recognize surprised and neutral emotions were lower than controls. ExP group improved recognition of almost all emotions, CBT group improved only happy emotions and SUP group did not improve any emotions. HDRS scores declined in all patient groups, ExP and CBT groups had lower scores than SUP. Conclusion: MDD patients recognized surprised and neutral emotions lower than controls. ExP improved ability to recognize almost all emotions, CBT improved only happy emotions, SUP did not improve at all. ExP, CBT and SUP all led to a reduction in MDD. ExP and CBT had comparable effects and both were more helpful than SUP.
- PublicationOpen AccessImprovement in attention and executive functions during isotretinoin treatment in patients with acne(2013-06-01) Deveci, ERDEM; Ozturk, AHMET; Kirpinar, Ismet; ENGIN, Ragip Ismail; MELIKOGLU, Mehmet; SAKAT, Selcen Caferoglu; DEMIR, Muhammet; CANPOLAT, Serpil; DEVECİ, ERDEM; ÖZTÜRK, AHMET; KIRPINAR, İSMETBackground and Design: We assessed attention, memory, verbal-linguistic ability, and executive functions in acne vulgaris patients before and during isotretinoin treatment.
- PublicationOpen AccessDevelopment of Hyperprolactinemia Induced by the Addition of Bupropion to Venlafaxine XR Treatment(2018-04-01) KILIÇ, Alperen; Ozturk, AHMET; Deveci, ERDEM; Kirpinar, Ismet; ÖZTÜRK, AHMET; DEVECİ, ERDEM; KIRPINAR, İSMETHyperprolactinemia is characterized by abnormally increased serum prolactin levels. Menstrual irregularities and hyperprolactinemia can be caused by a variety of medical conditions as well as due to the use of some psychopharmacological drugs, namely antipsychotics; it can also develop during antidepressant treatment. Bupropion is an antidepressant functioning via the inhibition of noradrenaline and dopamine reuptake. The endocrine and sexual adverse events of this agent are rare. In the literature, only one case reporting hyperprolactinemia or galactorrhea caused by bupropion use is available. Here, we present the case of a patient diagnosed with depressive disorder and receiving venlafaxine, who developed hyperprolactinemia and oligomenorrhea after the addition of bupropion the ongoing treatment and showed serum prolactin levels decreased to normal ranges shortly after the discontinuation of bupropion.
- PublicationOpen AccessA Treatment-Response Comparison Study of Resting-State Functional Magnetic Resonance Imaging Between Standard Treatment of SSRI and Standard Treatment of SSRI Plus Non-dominant Hand-Writing Task in Patients With Major Depressive Disorder(2021-09-01T00:00:00Z) BOYRAZ, Rabia Kevser; KIRPINAR, İSMET; YILMAZ, Onur; Ozyurt, Onur; KILIÇARSLAN, TEZER; ARALAŞMAK, Ayşe; BOYRAZ, RABIA KEVSER; KIRPINAR, İSMET; YILMAZ, ONUR; KILIÇARSLAN, TEZER; ARALAŞMAK, AYŞEBackground: Researches have recently shifted from functional/structural imaging studies to functional connectivity (FC) studies in major depressive disorder (MDD). We aimed to compare treatment response of two treatment groups before and after treatment, in terms of both with psychiatric evaluation scales and resting-state functional connectivity (RSFC) changes in order to objectively demonstrate the possible contribution of the non-dominant hand-writing exercise (NHE) effect on depression treatment.
- PublicationOpen AccessInvestigation of facial emotion recognition, alexithymia, and levels of anxiety and depression in patients with somatic symptoms and related disorders(2016-04-29) ÖZTÜRK, AHMET; KILIÇ, Alperen; DEVECİ, ERDEM; KIRPINAR, İSMET; ÖZTÜRK, AHMET; DEVECİ, ERDEM; KIRPINAR, İSMETBackground: The concept of facial emotion recognition is well established in various neuropsychiatric disorders. Although emotional disturbances are strongly associated with somatoform disorders, there are a restricted number of studies that have investigated facial emotion recognition in somatoform disorders. Furthermore, there have been no studies that have regarded this issue using the new diagnostic criteria for somatoform disorders as somatic symptoms and related disorders (SSD). In this study, we aimed to compare the factors of facial emotion recognition between patients with SSD and age- and sex-matched healthy controls (HC) and to retest and investigate the factors of facial emotion recognition using the new criteria for SSD. Patients and methods: After applying the inclusion and exclusion criteria, 54 patients who were diagnosed with SSD according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria and 46 age- and sex-matched HC were selected to participate in the present study. Facial emotion recognition, alexithymia, and the status of anxiety and depression were compared between the groups. Results: Patients with SSD had significantly decreased scores of facial emotion for fear faces, disgust faces, and neutral faces compared with age- and sex-matched HC (t=-2.88, P=0.005; t=-2.86, P=0.005; and t=-2.56, P=0.009, respectively). After eliminating the effects of alexithymia and depressive and anxious states, the groups were found to be similar in terms of their responses to facial emotion and mean reaction time to facial emotions. Discussion: Although there have been limited numbers of studies that have examined the recognition of facial emotion in patients with somatoform disorders, our study is the first to investigate facial recognition in patients with SSD diagnosed according to the DSM-5 criteria. Recognition of facial emotion was found to be disturbed in patients with SSD. However, our findings suggest that disturbances in facial recognition were significantly associated with alexithymia and the status of depression and anxiety, which is consistent with the previous studies. Further studies are needed to highlight the associations between facial emotion recognition and SSD.